

Special Issue

Nanomaterials for Cancer Diagnosis and Therapy

Message from the Guest Editors

The development of precisely engineered nanoparticles able to overcome biological barriers, specifically recognize and destroy a single type of cancer cell, and accumulate preferentially in tumours, offers a new and potent arsenal to oncologists. In this SI, we invite investigators to contribute original research articles and review articles that are related to the application of nanoparticles as multifunctional platforms in the treatment and early diagnosis of cancer. We are particularly interested in research directed toward improving the effectivity and selectivity properties of different nanoparticles for treatment or bioimaging purposes. Potential topics include, but are not limited to:

- Theranostic nanoparticles for cancer treatment
- Nanoparticles as contrast agents for bioimaging
- Nanoparticles as biosensors
- Novel therapies based on nanomaterials for cancer treatment and diagnosis
- Clinical studies and therapeutic and diagnostic efficacy of anti-cancer nanoparticles
- Biocompatibility and toxicity studies of nanoparticles for cancer treatment.

Guest Editors

Dr. Alejandro Baeza
Dr. Fernando Novio
Dr. Juan Luis Paris

Deadline for manuscript submissions

closed (31 May 2020)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed




mdpi.com/si/21904

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of
Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore
- Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).